Compare DexCom, Inc. (DXCM) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Banco Santander SA — how do they compare? DexCom, Inc. trades at $77.41 (market cap $28.06B), while Banco Santander SA trades at $13.66 (market cap $195.14B). The key difference: Banco Santander SA is far larger — about 7× DexCom, Inc.'s market cap, and Banco Santander SA pays a 2.01% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | SAN | |
|---|---|---|
Market Cap | $28.06B | $195.14B |
Sector | Health | Financials |
52-Week High | $89.53 | $14.37 |
52-Week Low | $54.84 | $8.40 |
Enterprise Value | $27.03B | — |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
SAN trades at $13.67, up 0.29% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported Q1 2026 EPS of $0.4144, beating expectations of $0.29, and maintains a strong net income margin of 26.72%. Recent developments include the acquisition of TSB and AI-driven efficiency initiatives targeting over $1.15 billion in business value.
Outlook is positive with analyst consensus at 64% buy ratings, supported by record profitability and a dividend yield from the recent $0.15 payout. Risks include declining operating cash flow, high debt levels, and antitrust probes in Spain. The stock offers value with a P/E of 13.73 and ROE of 16.18%, but investors should monitor cash flow trends and regulatory outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
